Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions ...

Dupixent – which is due for a verdict from the FDA as a COPD therapy later this month – was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used ...